bebig ruthenium-106 ophthalmic plaques have been used for treatment of uveal melanoma, retinoblastoma, melanoma of the iris and other special applications for many years. the plaques consist of a thin film of 106ru, a beta emitter, encapsulated in pure silver. the present work proposes a new mathematical eye model for ophthalmic brachytherapy dosimetry. this new model includes detailed descript...

  BEBIG Ruthenium-106 ophthalmic plaques have been used for treatment of uveal melanoma, retinoblastoma, melanoma of the iris and other special applications for many years. The plaques consist of a thin film of 106Ru, a beta emitter, encapsulated in pure silver. The present work proposes a new mathematical eye model for ophthalmic brachytherapy dosimetry. This new mod...

PURPOSE HDR (60)Co system has recently been developed and utilized for brachytherapy in many countries outside of the U.S. as an alternative to (192)Ir. In addition, the AccuBoost(®) technique has been demonstrated to be a successful non-invasive image-guided breast brachytherapy treatment option. The goal of this project is to evaluate the possibility of utilizing the BEBIG HDR (60)Co system f...

Introduction: The dwell time and transit time components contribute to the overall delivered dose to patients in high dose rate (HDR) brachytherapy treatments. The transit time results from source entry and exit as well as source movements between dwell positions. It depends on various parameters such as the source speed profile, source indexer distance to dwell position, and ...

PURPOSE To determine whether the computed dosimetry of a new ophthalmic plaque, EP917, when compared with the standard Collaborative Ocular Melanoma Study (COMS) plaques, could reduce radiation exposure to vision critical structures of the eye. METHODS AND MATERIALS One hundred consecutive patients with uveal melanoma treated with COMS radiation plaques between 2007 and 2010 were included in ...